George Scangos joins Voyager board in reunion with Biogen colleague Al Sandrock
George Scangos, a longtime CEO who has helmed a trio of marquee names in biotech, is returning to the brain and teaming up with a former Biogen colleague.
In his first big move since retiring as CEO of infectious disease drug developer Vir Biotechnology last month, Scangos is reuniting with Al Sandrock at the latter’s Voyager Therapeutics.
As of today, the 75-year-old Scangos becomes a board member of the biotech, whose pipeline spans the gamut of the brain — Alzheimer’s disease, ALS, Parkinson’s and other undisclosed central nervous system diseases with gene therapy programs allied with Neurocrine, Pfizer and Novartis.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters